Dermatology, Hair Care / 10.02.2026
Listening to the Skin Beneath Your Hair
Your scalp is speaking to you. The question is: are you listening?
We spend so much time thinking about our hair—the color, the cut, the style—that we often forget about the foundation it grows from. Your scalp is skin, just like the skin on your face, and it deserves the same attention and care. When we ignore what's happening beneath our hair, we miss important signals our body is sending us.
The scalp is one of the most neglected areas of our skincare routine. Hidden under layers of hair, it's easy to overlook until something goes wrong. But this skin is actually quite remarkable. It contains more hair follicles and oil glands than almost any other part of your body. Each follicle is surrounded by blood vessels, nerve endings, and sebaceous glands working together in a delicate balance.
Think about the last time you really paid attention to your scalp. Not just a quick scratch or a rushed shampoo, but actually checked in with how it feels. Is it tight? Dry? Oily? Does it tingle or feel sensitive? These sensations are your scalp's way of communicating its needs.
When your scalp is healthy, you probably don't think about it at all. It's comfortable, balanced, and quiet. But when something shifts—whether from stress, weather changes, new products, or hormonal fluctuations—your scalp lets you know. An itchy scalp is one of the most common ways your body tells you something needs attention. It might seem like a minor annoyance, but persistent itching often signals an underlying issue that shouldn't be ignored.
Dr. Mosnaim[/caption]
Dr. Giselle Mosnaim MD MS FACAAI
Allergist
Division of Allergy and Immunology
Department of Medicine
Northshore University Health System
REMIX-1/-2 Investigator
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment.
The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
Dr. King[/caption]
Brett King, MD, PHD
Dr. King was named an American Academy of Dermatology (AAD) “Patient Care Hero”
for his work treating patients with severe alopecia areata
Dermatology Physicians of Connecticut
Fairfield, Connecticut
MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of Alopecia Areata?
Response: Alopecia Areata (AA), an autoimmune form of hair loss, is common and its treatment has been revolutionized in the past ~3 years with approvals of 3 JAK inhibitors, bariticinib, ritlecitinib and deuruxolitinib. Prior to these approvals, off label treatments included the JAK inhibitors tofacitinib and ruxolitinib.
